Infinity Presents Positive Early Data on Therapy for NSCLC, Other Solid Tumors
News
Infinity Pharmaceuticals recently presented pre-clinical and clinical data from the company’s oral therapy candidate IPI-549 in solid tumors. The data was presented during the plenary session “PI3K Pathways in Immunology, ... Read more